Scientists test Next-Gen shot to block more Cancer-Causing viruses
NCT ID NCT05985681
Summary
This is an early-stage study to check the safety and immune response of a new vaccine called RG1-VLP. It aims to protect against additional types of human papillomavirus (HPV) that can cause cancer but aren't targeted by current vaccines like Gardasil-9. The trial will enroll 18 healthy women to test three different dose levels and monitor for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN PAPILLOMAVIRUS-RELATED CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johns Hopkins University/Sidney Kimmel Cancer Center
WITHDRAWNBaltimore, Maryland, 21287, United States
-
Medical University Vienna
NOT_YET_RECRUITINGVienna, A-1090, Austria
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Staten Island University Hospital
WITHDRAWNStaten Island, New York, 10305, United States
-
University of Alabama at Birmingham Cancer Center
WITHDRAWNBirmingham, Alabama, 35233, United States
-
University of Wisconsin Carbone Cancer Center - University Hospital
RECRUITINGMadison, Wisconsin, 53792, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.